Anand A Dalal

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. pmc The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
    Barbara P Yawn
    Olmsted Medical Center, University of Minnesota, Rochester, Minnesota, USA
    Int J Chron Obstruct Pulmon Dis 5:165-78. 2010
  2. doi request reprint Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy
    Anand A Dalal
    GlaxoSmithKline, 5 Moore Dr, Bide West, Mail Stop B 3153, Research Triangle Park, NC 27709, USA
    Respir Med 106:829-37. 2012
  3. pmc Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009
    Anand A Dalal
    US Health Outcomes, GlaxoSmithKline, Research Triangle Park, Durham, NC 27709, USA
    Int J Chron Obstruct Pulmon Dis 6:533-42. 2011
  4. pmc Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD
    Anand A Dalal
    GlaxoSmithKline, Research Triangle Park, 5 Moore Dr, Bide West, Durham, NC 27709, USA
    Respir Res 13:41. 2012
  5. ncbi request reprint Outcomes associated with timing of maintenance treatment for COPD exacerbation
    Anand A Dalal
    GlaxoSmithKline, Research Triangle Park, NC, USA
    Am J Manag Care 18:e338-45. 2012
  6. pmc Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease
    Arjun Chatterjee
    Department of Internal Medicine, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157, USA
    Respir Res 13:15. 2012
  7. pmc Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population
    Anand A Dalal
    GlaxoSmithKline, Research Triangle Park, NC, USA
    Int J Chron Obstruct Pulmon Dis 7:11-9. 2012
  8. ncbi request reprint Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD
    Anand A Dalal
    U S Health Outcomes, GlaxoSmithKline, Research Triangle Park, 5 Moore Drive, Mail Stop B 3153, Durham, NC 27709, USA
    Manag Care 20:46-50, 53-5. 2011
  9. doi request reprint Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population
    Anand A Dalal
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    COPD 8:293-9. 2011
  10. ncbi request reprint Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease
    Anand A Dalal
    GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    Respir Med 105:1516-22. 2011

Collaborators

Detail Information

Publications27

  1. pmc The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
    Barbara P Yawn
    Olmsted Medical Center, University of Minnesota, Rochester, Minnesota, USA
    Int J Chron Obstruct Pulmon Dis 5:165-78. 2010
    ....
  2. doi request reprint Rehospitalization risks and outcomes in COPD patients receiving maintenance pharmacotherapy
    Anand A Dalal
    GlaxoSmithKline, 5 Moore Dr, Bide West, Mail Stop B 3153, Research Triangle Park, NC 27709, USA
    Respir Med 106:829-37. 2012
    ..To determine clinical and economic outcomes following COPD-related hospitalization/emergency department (ED) care in patients receiving COPD maintenance therapy...
  3. pmc Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009
    Anand A Dalal
    US Health Outcomes, GlaxoSmithKline, Research Triangle Park, Durham, NC 27709, USA
    Int J Chron Obstruct Pulmon Dis 6:533-42. 2011
    ....
  4. pmc Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD
    Anand A Dalal
    GlaxoSmithKline, Research Triangle Park, 5 Moore Dr, Bide West, Durham, NC 27709, USA
    Respir Res 13:41. 2012
    ..COPD-related outcomes were compared between patients initiating fluticasone propionate-salmeterol 250/50 mcg (FSC) vs anticholinergics (ACs) following a moderate COPD exacerbation...
  5. ncbi request reprint Outcomes associated with timing of maintenance treatment for COPD exacerbation
    Anand A Dalal
    GlaxoSmithKline, Research Triangle Park, NC, USA
    Am J Manag Care 18:e338-45. 2012
    ..To examine the impact of timing of maintenance treatment initiation (early vs delayed) on risk of future exacerbations and costs in chronic obstructive pulmonary disease (COPD) patients...
  6. pmc Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease
    Arjun Chatterjee
    Department of Internal Medicine, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157, USA
    Respir Res 13:15. 2012
    ....
  7. pmc Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population
    Anand A Dalal
    GlaxoSmithKline, Research Triangle Park, NC, USA
    Int J Chron Obstruct Pulmon Dis 7:11-9. 2012
    ..Managing COPD symptoms and exacerbations through use of appropriate and adequate pharmacotherapy in this population may result in better COPD-related outcomes...
  8. ncbi request reprint Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 microg/50 microg combination versus tiotropium in commercially insured patients with COPD
    Anand A Dalal
    U S Health Outcomes, GlaxoSmithKline, Research Triangle Park, 5 Moore Drive, Mail Stop B 3153, Durham, NC 27709, USA
    Manag Care 20:46-50, 53-5. 2011
    ....
  9. doi request reprint Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population
    Anand A Dalal
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    COPD 8:293-9. 2011
    ..The purpose of this study was to evaluate their impact on healthcare utilization and costs in a managed care COPD population...
  10. ncbi request reprint Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease
    Anand A Dalal
    GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
    Respir Med 105:1516-22. 2011
    ..The purpose of this study was to evaluate the impact of comorbid CVD on healthcare utilization and costs in a COPD population...
  11. ncbi request reprint COPD-related healthcare utilization and costs after discharge from a hospitalization or emergency department visit on a regimen of fluticasone propionate-salmeterol combination versus other maintenance therapies
    Anand A Dalal
    GlaxoSmith Kline, Research Triangle Park, Durham, NC 27709, USA
    Am J Manag Care 17:e55-65. 2011
    ....
  12. pmc Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease
    Anand A Dalal
    US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    Int J Chron Obstruct Pulmon Dis 6:13-22. 2011
    ....
  13. pmc Validation of alternate modes of administration of the lung function questionnaire (LFQ) in subjects with smoking history
    Anand A Dalal
    United States Health Outcomes, GlaxoSmithKline, Durham, NC, USA
    Int J Chron Obstruct Pulmon Dis 5:425-34. 2010
    ..Our objective was to assess the usability and validity of additional questionnaire-administration modes, including Web-based, interactive voice response system (IVRS)-based, and interviewer-based modes...
  14. doi request reprint Costs of inpatient and emergency department care for chronic obstructive pulmonary disease in an elderly Medicare population
    Anand A Dalal
    GlaxoSmithKline, Research Triangle Park, NC 27709, USA
    J Med Econ 13:591-8. 2010
    ..The authors determined the costs and characteristics of COPD-related hospital-based healthcare in a Medicare population...
  15. doi request reprint Costs of COPD exacerbations in the emergency department and inpatient setting
    Anand A Dalal
    GlaxoSmithKline, 5 Moore Dr, Mail Stop 17 1355B, Research Triangle Park, NC 27709, USA
    Respir Med 105:454-60. 2011
    ..Treatment of exacerbations in the hospital setting is costly, but information concerning the component cost drivers of this care is scarce. Our objective was to describe and characterize costs of COPD care in the hospital setting...
  16. pmc Falls in people with chronic obstructive pulmonary disease: an observational cohort study
    M Roig
    Department of Physical Therapy, University of British Columbia, Vancouver, Canada
    Respir Med 105:461-9. 2011
    ..To investigate incidence, risk factors and impact of falls on health related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD)...
  17. pmc Direct costs of chronic obstructive pulmonary disease among managed care patients
    Anand A Dalal
    US Health Outcomes, GlaxoSmithKline, Research Triangle Park, Durham, NC 27709, USA
    Int J Chron Obstruct Pulmon Dis 5:341-9. 2010
    ..To estimate patient- and episode-level direct costs of chronic obstructive pulmonary disease (COPD) among commercially insured patients in the US...
  18. doi request reprint Economic burden of rhinitis in managed care: a retrospective claims data analysis
    Anand A Dalal
    GlaxoSmithKline, Research Triangle Park, North Carolina, USA
    Ann Allergy Asthma Immunol 101:23-9. 2008
    ..Furthermore, the direct costs of chronic rhinitis have not been evaluated and potential differences in health care use and costs of allergic rhinitis have not been examined...
  19. pmc Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients
    Anand A Dalal
    US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA
    Int J Chron Obstruct Pulmon Dis 5:179-87. 2010
    ..To estimate the cost-effectiveness of fluticasone propionate-salmeterol combination (FSC) compared to salmeterol for maintenance therapy in severe chronic obstructive pulmonary disease (COPD)...
  20. doi request reprint Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD
    Anand A Dalal
    GlaxoSmithKline, Research Triangle Park, NC, USA
    J Med Econ 12:339-47. 2009
    ....
  21. doi request reprint Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD
    Stephanie R Earnshaw
    RTI Health Solutions, Research Triangle Park, NC, USA
    Respir Med 103:12-21. 2009
    ..We examine the lifetime cost-effectiveness of treatment with fluticasone propionate/salmeterol (500/50 microg) compared with no maintenance treatment in COPD in the US...
  22. ncbi request reprint Evaluating patient-reported outcome measurement comparability between paper and alternate versions, using the lung function questionnaire as an example
    Anand A Dalal
    GlaxoSmithKline, Durham, NC, USA
    Value Health 14:712-20. 2011
    ..The goal of this study was to provide recommended steps to assess measurement comparability using a crossover study design and to demonstrate these steps using a short patient-reported outcome (PRO) instrument as an example...
  23. pmc Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction
    Barbara P Yawn
    Olmsted Medical Center, Department of Research, Rochester, MN, USA
    Int J Chron Obstruct Pulmon Dis 5:1-10. 2010
    ....
  24. pmc Prevalence of airway obstruction assessed by lung function questionnaire
    Matthew L Mintz
    Department of Medicine, George Washington University School of Medicine, Washington, DC, USA
    Mayo Clin Proc 86:375-81. 2011
    ..To estimate the prevalence of unidentified chronic obstructive pulmonary disease (COPD) and determine the screening accuracy of the Lung Function Questionnaire (LFQ)...
  25. ncbi request reprint Qualitative Development of the Rhinitis Control Assessment Test (RCAT), an Instrument for Evaluating Rhinitis Symptom Control
    Robert A Nathan
    1 Asthma and Allergy Associates, Colorado Springs, Colorado, USA 2 GlaxoSmithKline, Research Triangle Park, North Carolina, USA 3 Allergy and Asthma Medical Group and Research Center, San Diego, California, USA 4 Kaiser Permanente, San Diego, California, USA 5 House Ear Clinic, Los Angeles, California, USA 6 George Washington University School of Medicine, Washington, DC, USA 7 RTI Health Solutions, Research Triangle Park, North Carolina, USA
    Patient 3:91-9. 2010
    ....
  26. ncbi request reprint Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States
    Jeetvan G Patel
    Pharmacy Administration and Public Health, University of Houston, Houston, TX, USA US Health Outcomes, GlaxoSmithKline, Durham, NC, USA
    Int J Chron Obstruct Pulmon Dis 9:289-300. 2014
    ..To review and summarize existing literature on the indirect burden of chronic obstructive pulmonary disease (COPD) in the US...
  27. doi request reprint Changes in COPD demographics and costs over 20 years
    Christopher M Blanchette
    Department of Public Health Sciences, University of North Carolina, Charlotte, NC 28223, USA
    J Med Econ 15:1176-82. 2012
    ..The purpose of this study was to examine the changes in COPD costs over 20 years and assess total direct cost trends over the last 10...